Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain

详细信息    查看全文

• 作者：Christina L. Brunnquell ; Reinier Hernandez ; Stephen A. Graves ; Ivy Smit-Oistad ; Robert J. Nickles ; Weibo Cai ; M. Elizabeth Meyerand and Masatoshi Suzuki
• 刊名：Contrast Media & Molecular Imaging
• 出版年：2016
• 出版时间：September/October 2016
• 年：2016
• 卷：11
• 期：5
• 页码：371-380
• 全文大小：811K
• ISSN：1555-4317

文摘

Manganese-enhanced magnetic resonance imaging (MRI) is an established neuroimaging method for signal enhancement, tract tracing, and functional studies in rodents. Along with the increasing availability of combined positron emission tomography (PET) and MRI scanners, the recent development of the positron-emitting isotope ⁵²Mn has prompted interest in the use of Mn²⁺ as a dual-modality contrast agent. In this work, we characterized and compared the uptake of systemically delivered Mn²⁺ and radioactive ⁵²Mn²⁺ in the rat brain for MRI and PET, respectively. Additionally, we examined the biodistribution of two formulations of ⁵²Mn²⁺ in the rat. In MRI, maximum uptake was observed one day following delivery of the highest MnCl₂ dose tested (60 mg/kg), with some brain regions showing delayed maximum enhancement 2–4 days following delivery. In PET, we observed low brain uptake after systemic delivery, with a maximum of approximately 0.2% ID/g. We also studied the effect of final formulation vehicle (saline compared with MnCl₂) on ⁵²Mn²⁺ organ biodistribution and brain uptake. We observed that the addition of bulk Mn²⁺ carrier to ⁵²Mn²⁺ in solution resulted in significantly reduced ⁵²Mn²⁺ uptake in the majority of organs, including the brain. These results lay the groundwork for further development of ⁵²Mn PET or dual Mn-enhanced PET–MR neuroimaging in rodents, and indicate several interesting potential applications of ⁵²Mn PET in other organs and systems. Copyright